
Sign up to save your podcasts
Or


First we had alpha, beta, and delta, and now we have hundreds of sublineages just from omicron alone. Virologist Dr. Andy Pekosz returns to the podcast to talk with Dr. Josh Sharfstein about how experts are keeping track of so many variations of SARS-CoV-2, which advantageous mutations most lineages are picking up to help them spread, the clinical impacts on treatments and vaccines, and why COVID-19 is not yet seasonal.
By The Johns Hopkins Bloomberg School of Public Health4.6
618618 ratings
First we had alpha, beta, and delta, and now we have hundreds of sublineages just from omicron alone. Virologist Dr. Andy Pekosz returns to the podcast to talk with Dr. Josh Sharfstein about how experts are keeping track of so many variations of SARS-CoV-2, which advantageous mutations most lineages are picking up to help them spread, the clinical impacts on treatments and vaccines, and why COVID-19 is not yet seasonal.

43,580 Listeners

40 Listeners

5 Listeners

27 Listeners

5 Listeners

262 Listeners

56,524 Listeners

495 Listeners

9 Listeners

45 Listeners

93 Listeners

16,355 Listeners

16 Listeners

4,752 Listeners

2 Listeners

4,486 Listeners

391 Listeners

6,552 Listeners

25 Listeners

6,389 Listeners

236 Listeners

65 Listeners

164 Listeners

98 Listeners